Literature DB >> 6307807

Involvement of the cytotoxic/suppressor T-cell subset in liver tissue injury of patients with acute and chronic liver diseases.

G R Pape, E P Rieber, J Eisenburg, R Hoffmann, C M Balch, G Paumgartner, G Riethmüller.   

Abstract

So far, phenotypic and functional analyses of cytotoxic lymphocytes in viral hepatitis, as well as in primary biliary cirrhosis, have focused on circulating lymphocyte subpopulations, whereas their occurrence and distribution at the involved site, namely the liver, remain largely unknown. In the present study, monoclonal antibodies were used to characterize both circulating and liver-tissue-infiltrating lymphocyte subsets in acute cytomegalovirus hepatitis, in chronic B-virus hepatitis, and in primary biliary cirrhosis. Special emphasis was laid on the cytotoxic/suppressor T-cell subset. Total T cells were identified by the monoclonal antibody T411. The monoclonal antibody T811 was used to identify the cytotoxic/suppressor T-cell subset, which comprises virus-specific, altered self, and alloreactive cytolytic T lymphocytes and their precursors, a fraction of killer and natural killer cells. Furthermore, killer and natural killer cells were identified more specifically by the monoclonal antibody. HNK1. Irrespective of the number of cytotoxic/suppressor T cells in peripheral blood, these cells (T811 phenotype) were accumulated in the liver at the site of tissue injury. The preponderance of this lymphocyte subset at the site of tissue injury suggests an important role for these cells in the mechanism leading to tissue injury.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307807

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  33 in total

1.  Localisation of intrahepatic interleukin 6 in patients with acute and chronic liver disease.

Authors:  S Kakumu; A Fukatsu; T Shinagawa; S Kurokawa; A Kusakabe
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

2.  Immunoelectron microscopic observations on Leu-7 positive cells in virus-related chronic liver diseases.

Authors:  H Himeno; H Enzan; T Saibara; S Onishi; Y Yamamoto
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

3.  Natural killer activity in patients with chronic hepatitis treated with OK432, interferon, adenine arabinoside and glycyrrhizin.

Authors:  T Wada; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1987-06

4.  Immunohistochemical study of HLA class 1 antigens on the hepatocytes of patients with chronic hepatitis B.

Authors:  K Manabe; G Yamada; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1986-08

5.  Clonal analysis of liver-derived T cells of patients with primary biliary cirrhosis.

Authors:  R M Hoffmann; G R Pape; U Spengler; E P Rieber; J Eisenburg; J Döhrmann; G Paumgartner; G Riethmüller
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

6.  Functional characterization of peripheral blood lymphocytes in chronic HBsAg carriers.

Authors:  G J Alexander; M Mondelli; N V Naumov; K T Nouriaria; D Vergani; D Lowe; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

7.  Plasma cells in acute hepatitis: an ultrastructural study.

Authors:  K A Bardadin; P J Scheuer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

Review 8.  Immunological aspects of chronic active hepatitis.

Authors:  S Vento; A L Eddleston
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

9.  Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of pro-inflammatory cytokines.

Authors:  R C Ayres; J M Neuberger; J Shaw; R Joplin; D H Adams
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

10.  Cytomegalovirus hepatitis: characterization of the inflammatory infiltrate in resistant and susceptible mice.

Authors:  S D Olver; P Price; G R Shellam
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.